Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Thoracic Malignancies
•
Medical Oncology
Would you use combination of weekly low dose carboplatin and Taxol in patient with small cell lung cancer with poor performance status or cytopenia?
Related Questions
In light of the 2024 Shkreli Awards, how do you address patient concerns regarding the 240mg versus 960mg dose of sotorasib?
Do you tell your patients with epithelioid subtype mesothelioma following gross resection and adjuvant cis/pemetrexed that they have completed "curative intent" treatment?
How would you approach the management of a patient with stage IIIA lung adenocarcinoma and multifocal hepatocellular carcinoma with Child-Pugh A cirrhosis?
How do you sequence targeted therapy and immunotherapy in patients with metastatic lung adenocarcinoma with EGFR exon 20 insertion mutations?
Has the MARS data for mesothelioma changed whether you would recommend surgery for these patients?
In what situations would immunotherapy alone be appropriate for non-metastatic NSCLC?
Did NRG LU004 demonstrate safety with hypofractionated lung radiation and concurrent ICI?
Would you offer consolidative durvalumab after chemoRT for an isolated mediastinal recurrence of NSCLC that occurred during adjuvant pembrolizumab given for the initial lung cancer?
Would you consider using IO alone for lung cancer patients who are PDL1 <1 but have high TMB?
What is your approach to obtain tissue diagnosis for a patient with a lung primary and spine metastasis?
